SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq:SOPH) reported outcomes of its 2026 Annual General Meeting held on June 22, 2026. Shareholders elected co-founder Dr. Jurgi Camblong as Executive Chairman and Ross Muken to the Board; Muken becomes CEO effective July 1, 2026.
All AGM proposals passed, including director and committee elections, Board and Executive Committee compensation maxima, an amendment aligning Articles with the 2021 Equity Incentive Plan share replenishment, approval of 2025 financial statements and ESG Impact Summary, re-election of PwC as auditor, and new governance measures such as a rotating Lead Independent Director and regular executive sessions of independent directors.
Positive
- CEO transition: Ross Muken to become CEO July 1, 2026
- Co-founder Jurgi Camblong elected Executive Chairman with 99.79% support
- All shareholder proposals, including compensation maxima, approved at 2026 AGM
- Articles aligned with 2021 Equity Incentive Plan share replenishment
- Governance enhancements: rotating Lead Independent Director and independent sessions
Negative
- 2025 net loss carried forward rather than distributing a profit
- Equity plan share replenishment may imply future shareholder dilution
News Market Reaction – SOPH
In the Jun 22 session, SOPH declined 2.20%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Equity offering priced | Negative | +6.3% | Company priced $50M ordinary share offering, but shares rose despite dilution. |
| Jun 16 | Equity offering proposed | Negative | +6.3% | Proposed underwritten public share offering under F-3 shelf; stock moved higher. |
| Jun 10 | Leadership transition | Neutral | -3.3% | Announced CEO transition and governance changes ahead of AGM; shares fell afterward. |
| Jun 04 | Cancer center MOU | Positive | +3.8% | Strategic MOU with MSK on precision oncology hub; stock reacted positively. |
| May 13 | UK testing partnership | Positive | -2.6% | Synnovis partnership to expand ctDNA testing; news was positive but shares declined. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent SOPH news often shows divergence, with equity offerings trading higher and at least one partnership selling off despite positive fundamentals.
Key Terms
equity incentive plan financial
articles of association regulatory
independent proxy regulatory
rule 10b5-1(c) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026
ROLLE,
The appointments mark an important milestone in SOPHiA GENETICS' continued evolution as it advances its mission to transform healthcare through Ai-enabled, data-driven medicine. All proposals presented to the AGM were approved by the shareholders.
"Co-founding SOPHiA GENETICS and serving as CEO over the past 15 years has been one of the greatest privileges of my professional life," said Jurgi Camblong, co-founder and newly elected Chairman of the Board of Directors of SOPHiA GENETICS. "What makes me proud is not only how far we have come, but the extraordinary people, partners, and customers who have helped shape our mission along the way. As we enter our next chapter, I am energized to work alongside Ross as he assumes the role of CEO, and to focus on my own contribution on the long-term strategic, scientific, and technological direction of the Company."
"SOPHiA GENETICS is entering one of the most exciting moments in its history, with strong commercial momentum and growing demand for Ai-powered, data-driven medicine," said Ross Muken, newly elected Board member and incoming Chief Executive Officer of SOPHiA GENETICS, effective July 1, 2026. "What gives me the greatest confidence is the strength of our mission, our differentiated technology, and most importantly, our people. As we enter this next chapter, I am incredibly energized by the opportunity ahead and confident in our ability to continue scaling our impact globally while delivering meaningful innovation for patients, providers, and biopharma partners."
In addition to Dr. Camblong, the following directors standing for re-election were re-elected to the Board of Directors for a term of office of one year, expiring at the conclusion of the 2027 Annual General Meeting:
- Troy Cox
- Tomer Berkovitz
- Jean-Michel Cosséry
- Kathy Hibbs
- Didier Hirsch
- Vincent Ossipow
The following persons standing for election were elected to the Board of Directors for a term of office of one year for the first time:
- Ross Muken
The following members of the Board of Directors were re-elected as members of the Compensation Committee for a term of office of one year:
- Kathy Hibbs
- Jean-Michel Cosséry
- Vincent Ossipow
Following the meeting, the Board of Directors re-appointed Kathy Hibbs as Chair of the Compensation Committee.
Compensation Votes
Shareholders approved the maximum aggregate compensation of the Board of Directors for the period from the 2026 Annual General Meeting to the 2027 Annual General Meeting, the maximum aggregate fixed compensation of the Executive Committee for the financial year 2027, and the maximum aggregate variable compensation of the Executive Committee for the financial year 2026, in each case as proposed by the Board.
Amendment to the Articles of Association
Shareholders approved the proposed amendment to Article 4b of the Articles of Association, giving effect to the annual share replenishment under the Company's 2021 Equity Incentive Plan to align the Articles of Association with the share replenishment described in the Plan, which was already authorized at the time of the Company's initial public offering. The resolution was approved by the two-thirds majority of shares represented at the meeting as required under Swiss law.
Annual Report, ESG Impact Summary, Appropriation of Result and Discharge
Shareholders approved the 2025 Management Report, the Annual Financial Statements and the Consolidated Financial Statements for the financial year 2025, acknowledged the Auditors' Reports, approved the appropriation of the 2025 financial result (carry-forward of the net loss), and granted discharge to the members of the Board of Directors and the Executive Committee for the 2025 financial year. On a consultative basis, shareholders also approved the 2025 ESG Impact Summary (Sustainability Report).
Auditors and Independent Proxy
The meeting re-elected PricewaterhouseCoopers SA as external auditors for the 2026 financial year and PHC Notaires as independent proxy until the conclusion of the 2027 ordinary Annual General Meeting.
Governance
In view of Dr. Camblong's election as Executive Chairman, the Board introduced a Lead Independent Director role, rotating annually among the Chairs of its independent Board committees. The Board will also hold standing executive sessions of its independent directors at each meeting. Together with an independent majority on the Board and fully independent committees, these arrangements give SOPHiA GENETICS a clear, robust governance framework for its next chapter.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is an Ai-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an Ai platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's leadership transition and governance arrangements, its strategic, scientific and technological direction, anticipated commercial momentum and demand for its solutions, and its ability to scale its impact and deliver innovation for patients, providers and biopharma partners. Forward-looking statements are generally identified by words such as "will", "expect", "believe", "confident", "energized", "continue", "anticipate", "intend" and similar expressions. These statements reflect management's current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 20-F and in subsequent reports furnished to or filed with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-publishes-results-of-the-2026-annual-general-meeting-302806355.html
SOURCE SOPHiA GENETICS